4-(4-甲氧基苯基)-2,2-二甲基-4-氧代丁酸 | 15118-48-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-(4-甲氧基苯基)-2,2-二甲基-4-氧代丁酸
• 英文名称: 4-(4-methoxyphenyl)-2,2-dimethyl-4-oxobutanoic acid
• 英文别名: 4-(4-methoxyphenyl)-2,2-dimethyl-4-oxobutyric acid；2.2-Dimethyl-4-4-oxo-buttersaeure；2.2-Dimethyl-4(p-methoxy-phenyl)-4-oxo-buttersaeure；2,2-Dimethyl-4-(4-methoxyphenyl)-4-oxobutyric acid
• CAS: 15118-48-6
• 化学式: C₁₃H₁₆O₄
• mdl: MFCD01320131
• 分子量: 236.268
• InChiKey: MWWLDHHCRLWJJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.384
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  4-(4-甲氧基苯基)-2,2-二甲基-4-氧代丁酸 在 氢溴酸 作用下， 以90%的产率得到4-(4-Hydroxyphenyl)-2,2-dimethyl-4-oxobutanoic acid
  参考文献：
  名称：

  4,5-Dihydropyridazin-3-one derivatives as histamine H3 receptor inverse agonists

  摘要：

  H3R structure-activity relationships for a new class of 4,5-dihydropyridazin-3-one H3R antagonists/inverse agonists are disclosed. Modification of the 4,5-dihydropyridazinone moiety to block in vivo metabolism identified 4,4-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one 22 as a lead candidate demonstrating potent in vivo functional H3R antagonism in the rat dipsogenia model and robust wake promoting activity in the rat EEG/EMG model. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.037
• 作为产物：
  描述：

  2,2-Dimethoxy-5-(4-methoxy-phenyl)-3,3-dimethyl-2,3-dihydro-furan 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 生成 4-(4-甲氧基苯基)-2,2-二甲基-4-氧代丁酸
  参考文献：
  名称：

  Scarpati,R. et al., Gazzetta Chimica Italiana, 1967, vol. 97, p. 654 - 664

  摘要：

  DOI：

文献信息

• Iridium-Catalyzed Asymmetric Hydrogenation of β,γ-Unsaturated γ-Lactams: Scope and Mechanistic Studies
  作者：Qianjia Yuan、Delong Liu、Wanbin Zhang

  DOI：10.1021/acs.orglett.7b00171

  日期：2017.3.3

  asymmetric hydrogenation of β,γ-unsaturated γ-lactams using an iridium–phosphoramidite complex is reported. The chiral γ-lactams were obtained in excellent yields and enantioselectivities (up to 99% yield and 99% ee). The mechanistic studies indicated that the reduced products were obtained via the hydrogenation of the N-acyliminium cations, generated from β,γ-unsaturated γ-lactams, which was verified

  据报道，使用铱-亚磷酰胺络合物可以有效地不对称地氢化β，γ-不饱和γ-内酰胺。以优异的产率和对映选择性（高达99％的产率和99％的ee）获得手性γ-内酰胺。机理研究表明，还原产物是通过氢化由β，γ-不饱和γ-内酰胺生成的N-酰基亚胺阳离子而获得的，该产物已通过1 H NMR分析证实。反应在0.1mol％的降低的催化剂负载下进行，并且还原的产物可以转化为两种潜在的生物活性化合物。提供了合成手性γ-内酰胺的新途径。
• 4-Phenoxypiperidine pyridazin-3-one histamine H3 receptor inverse agonists demonstrating potent and robust wake promoting activity
  作者：Robert L. Hudkins、Allison L. Zulli、Reddeppa reddy Dandu、Ming Tao、Kurt A. Josef、Lisa D. Aimone、R. Curtis Haltiwanger、Zeqi Huang、Jacquelyn A. Lyons、Joanne R. Mathiasen、Rita Raddatz、John A. Gruner

  DOI：10.1016/j.bmcl.2012.01.026

  日期：2012.2

  Structure-activity relationships for a series of phenoxypiperidine pyridazin-3-one H3R antagonists/inverse agonists are disclosed. The search for compounds with improved hERG and DAT selectivity without the formation of in vivo active metabolites identified 6-[4-(1-cyclobutyl-piperidin-4-yloxy)phenyl]- 4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one 17b. Compound 17b met discovery flow criteria, demonstrated potent H3R functional antagonism in vivo in the rat dipsogenia model and potent wake activity in the rat EEG/EMG model at doses as low as 0.1 mg/kg ip. (C) 2012 Elsevier Ltd. All rights reserved.
• ORZALESI H.; CHEVALLET P.; BERGE G.; BOUCARD M.; SERRANO J.-J.; PRIVAT G.+, EUR. J. MED. CHEM., 1978, 13, NO 3, 259-264
  作者：ORZALESI H.、 CHEVALLET P.、 BERGE G.、 BOUCARD M.、 SERRANO J.-J.、 PRIVAT G.+

  DOI：——

  日期：——
• Scarpati,R. et al., Gazzetta Chimica Italiana, 1967, vol. 97, p. 654 - 664
  作者：Scarpati,R. et al.

  DOI：——

  日期：——
• 4,5-Dihydropyridazin-3-one derivatives as histamine H3 receptor inverse agonists
  作者：Robert L. Hudkins、Lisa D. Aimone、Reddeppa reddy Dandu、Derek Dunn、John A. Gruner、Zeqi Huang、Kurt A. Josef、Jacquelyn A. Lyons、Joanne R. Mathiasen、Ming Tao、Allison L. Zulli、Rita Raddatz

  DOI：10.1016/j.bmcl.2011.11.037

  日期：2012.1

  H3R structure-activity relationships for a new class of 4,5-dihydropyridazin-3-one H3R antagonists/inverse agonists are disclosed. Modification of the 4,5-dihydropyridazinone moiety to block in vivo metabolism identified 4,4-dimethyl-6-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one 22 as a lead candidate demonstrating potent in vivo functional H3R antagonism in the rat dipsogenia model and robust wake promoting activity in the rat EEG/EMG model. (C) 2011 Elsevier Ltd. All rights reserved.